Linagliptin/Metformin

Linagliptin and Metformin, the active ingredients in Linagliptin/Metformin, are a DPP‑4 inhibitor and a biguanide presented as an oral tablet for oral use. They are indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when combined with diet and exercise.

GNH USA supplies Linagliptin/Metformin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Linagliptin/Metformin is used in the treatment of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

- Type 2 diabetes mellitus (monotherapy): provides glycaemic control as initial oral therapy when diet and exercise are insufficient. - Type 2 diabetes mellitus (combination therapy): added to other antidiabetic agents to achieve additional HbA1c reduction. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise measures to improve overall glucose management.

Linagliptin/Metformin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often transient. - Headache: mild cranial discomfort. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication, mainly linked to metformin. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe hypersensitivity reactions: including skin rash, Stevens‑Johnson syndrome, or anaphylaxis.

When prescribing Linagliptin/Metformin, clinicians should observe several precautionary measures to minimise risk. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia monitoring: caution when combined with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Drug interaction review: assess concomitant medications that may affect metformin or linagliptin levels. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Linagliptin/Metformin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Iodinated contrast agents in patients with reduced renal function: can precipitate metformin‑associated lactic acidosis. - Insulin or sulfonylureas: combined use raises risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may reduce metformin clearance, requiring renal monitoring. - ACE inhibitors or ARBs: may modestly increase risk of metformin‑related lactic acidosis. - Beta‑blockers: can mask hypoglycaemic symptoms, necessitating patient education.